Nathan Dowden Sells 15,000 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan Dowden sold 15,000 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $15.33, for a total transaction of $229,950.00. Following the completion of the sale, the chief operating officer owned 198,588 shares in the company, valued at approximately $3,044,354.04. This trade represents a 7.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Entrada Therapeutics Stock Performance

Shares of TRDA stock opened at $15.75 on Wednesday. The stock has a market capitalization of $611.42 million, a price-to-earnings ratio of -4.55 and a beta of -0.09. Entrada Therapeutics, Inc. has a one year low of $4.93 and a one year high of $16.19. The company’s 50-day simple moving average is $12.81 and its 200-day simple moving average is $10.82.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.38. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%.The firm had revenue of $1.30 million during the quarter, compared to analyst estimates of $7.41 million. As a group, research analysts forecast that Entrada Therapeutics, Inc. will post -4.22 EPS for the current year.

Hedge Funds Weigh In On Entrada Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC increased its stake in Entrada Therapeutics by 11.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 19,465 shares of the company’s stock valued at $246,000 after buying an additional 1,970 shares during the period. Hsbc Holdings PLC lifted its stake in shares of Entrada Therapeutics by 83.1% in the 1st quarter. Hsbc Holdings PLC now owns 38,137 shares of the company’s stock worth $472,000 after acquiring an additional 17,304 shares during the period. Invesco Ltd. lifted its stake in shares of Entrada Therapeutics by 41.1% in the 4th quarter. Invesco Ltd. now owns 41,033 shares of the company’s stock worth $422,000 after acquiring an additional 11,958 shares during the period. XTX Topco Ltd boosted its holdings in shares of Entrada Therapeutics by 26.4% in the fourth quarter. XTX Topco Ltd now owns 117,668 shares of the company’s stock valued at $1,210,000 after acquiring an additional 24,589 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of Entrada Therapeutics by 9.5% in the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock valued at $10,740,000 after acquiring an additional 90,339 shares in the last quarter. 86.39% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a research report on Wednesday, February 18th. Wall Street Zen downgraded shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Cantor Fitzgerald started coverage on shares of Entrada Therapeutics in a research note on Wednesday, April 1st. They set an “overweight” rating for the company. Oppenheimer increased their target price on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a report on Monday, April 6th. Finally, Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $19.00.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.